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The Illusion of “Optimal”
Platelet Inhibition*
Steven R. Steinhubl, MD
Danville, Pennsylvania
Real knowledge is to know the extent of one’s ignorance.
—Confucius (1)
Having the ability to measure whether and how much a drug
is able to influence platelet function ex vivo has led to some
remarkable contributions to cardiovascular medicine over the
last several decades. For example, the nearly 40-year journey for
aspirin to go from a hypothesized to a proven therapy for ischemic
heart disease may have never occurred if not for a series of
mechanistic investigations of its effects on platelet function (2).
See pages 259 and 268
The entire thienopyridine class of antiplatelet agents may
have been forever relegated to the trash heap of failed
pharmaceutical entities if not for the fortuitous finding that
it prevented adenosine diphosphate (ADP)-induced platelet
aggregation after it initially failed for its proposed use as an
anti-inflammatory agent (3). And the parenteral platelet
glycoprotein (GP) IIb/IIIa inhibitors are a drug class that
was specifically designed around their ability to potently
inhibit platelet aggregation. But even with these notable
successes, historically, platelet function testing has proven to
be a somewhat unreliable and confusing “crystal ball”—
inconsistent in its ability to predict what, if any, antithrom-
botic efficacy an agent may have—and still of no proven
clinical use in guiding individual therapy. Nonetheless,
because our ability to adequately tame the platelet is so
critical for the successful treatment and prevention of
arterial thrombosis, and because, as of yet, we have no viable
testing alternative, ex vivo platelet function assessments
have and will continue to play a substantial role in clinical
research and drug development.
To the busy clinician, the constant barrage of academic
research and industry marketing focusing solely on platelet
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ontents of this paper to disclose.function testing results and the achievement of “optimal”
platelet inhibition might imply a level of understanding
greater than what truly exists. Further improving our real
knowledge of assessing platelet function and how to inter-
pret its results requires a deeper appreciation and under-
standing of the 3 basic issues summarized in the following
text.
There are hundreds of variations and methods to test platelet
function; all generate different results. The origins of plate-
et function testing date back over 100 years to the earliest
escription of bleeding times, and the first ex vivo platelet
unction test was described in 1929 (2). Since then, every
anner of platelet disintegration, adhesion, stickiness, ag-
regation, agglutination, and activation has been quanti-
ated in some form as a measure of platelet activity. The test
ample for these various tests is whole blood or platelet-rich
lasma and has in some cases been stored overnight, spun in
lass jars, poured over glass beads, mixed with fibrinogen-
oated beads, sucked through capillary tubes or pin holes in
ollagen discs, stirred, or otherwise “assaulted” in a number
f ways. Most of the time, the blood or plasma is mixed with
ome kind of an antithrombotic agent at varying amounts;
ften it is citrate, but sometimes heparin, hirudin, or a
umber of other compounds. Next, a platelet agonist is
sually added such as ADP, collagen, thromboxane, throm-
in, and many others, with the concentration chosen some-
hat arbitrarily and with up to a 100-fold variation among
aboratories. What is critical to appreciate is that every one
f these variations, both big and small, can have a profound
mpact on measured platelet function. As a simple example,
P IIb/IIIa inhibitors can be said to inhibit platelet
ggregation anywhere from only 30% to nearly 100%,
epending on the agonist and its concentration (4).
Even if we focus on just 3 somewhat similar and common
ethods of platelet function testing, surprising differences
re found. Light transmittance aggregometry (LTA), the
erifyNow P2Y12 assay (Accumetrics, San Diego, Califor-
ia), and the Multiplate device (Roche, Basel, Switzerland)
re all based on the same general premise of adding an
gonist to a sample obtained through venipuncture and
easuring changes to the sample over time due to platelet
aggregation.” The blood samples are drawn into citrated
ubes for the VerifyNow P2Y12 assay and commonly for
TA, but hirudin is recommended for the Multiplate. For
TA, the blood is next centrifuged to yield platelet-rich
lasma, whereas whole blood is used in both the VerifyNow
2Y12 assay and Multiplate, but for the latter, the blood is
iluted 2:1 with saline. The platelet agonist, for example,
DP, is next added. For the Multiplate and VerifyNow
2Y12 assay, the concentration is set, but in the VerifyNow
2Y12 assay, prostaglandin E1 is added to the ADP. With
TA, the concentration is operator dependent, with con-
entrations commonly varying from 0.1 to 20 mol/l.
ollowing the mixing of agonist and sample, an aggregation
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279curve is then generated based on changes over time in
measured light passing through the sample for LTA and
VerifyNow P2Y12 assay, or changes in electrical impedance
for Multiplate. The most striking difference among the 3
testing platforms is that each measures something com-
pletely different on these generated curves, and then reports
that measure as platelet function. In the Multiplate, the area
under the curve is reported. For VerifyNow P2Y12 assay, it
is the slope of the initial portion of the curve. And for LTA,
it is operator dependent, but it is most typically the maximal
height of the curve, although the final height, and more
rarely the slope, have also been reported.
What all of this variability tells us is that our search for
“optimal” platelet inhibition will need to come with a very
detailed roadmap that is specific for the type of test, the
appropriate sample preparation, and the “correct” agonist(s)
and concentration(s).
The ability to inhibit platelet function ex vivo does not
guarantee clinical antithrombotic efﬁcacy. One of the land-
mark studies of modern cardiovascular medicine was the
Canadian multicenter trial, proving that aspirin was signif-
icantly more effective than placebo in decreasing cardiac
events, including cardiac death, in patients with unstable
angina (5). What is often forgotten about this trial is that it
included randomization to another antiplatelet agent, sul-
finpyrazone. Although it is likely you have never prescribed
sulfinpyrazone, at that time, it was considered by some to be
“. . . one of the most effective platelet inhibitors currently
available . . .” based on ex vivo platelet function testing (6).
Clinically, however, it provided no antithrombotic benefit,
and in the final analysis of the study, sulfinpyrazone-treated
patients were grouped with the placebo arm.
Within the last decade, the best examples of a platelet
inhibition–antithrombotic efficacy disconnect is exemplified
by the string of failed oral GP IIb/IIIa antagonists. All 4
agents evaluated in large phase III trials significantly and
substantially inhibited platelet aggregation greater than
their controls over a 24-h period. Although it was not
surprising that all of these agents increased bleeding, what
was unanticipated and still not well understood was that
their use did not even lead to a trend in improved anti-
thrombotic efficacy, and instead caused a significant increase
in mortality and increased myocardial infarction (MI) rates
among acute coronary syndrome patients (7).
Most recently, 2 promising antiplatelet drugs, vorapaxar
and cangrelor, failed to show significant clinical antithrom-
botic efficacy in large-scale phase III trials, despite achieving
greater levels of platelet inhibition based on separate ex vivo
testing (8–10).
The message from these agents seems clear: the ability to
inhibit platelet aggregation ex vivo is an unreliable surrogate
for clinical antithrombotic efficacy, especially between drug
classes and when considering the impact on the population.
Therefore, any attempt to identify an “optimal” level of plateletinhibition will need to be drug specific and is unlikely to be
additive between classes (unlike targeting a specific blood
pressure and achieving that level with several agents).
Measured platelet function may have more to do with the
plasma than the platelets. No matter how platelet function
is tested in the clinical setting, a lot more than just platelets
are being tested. Whether whole blood or platelet-rich
plasma is used, the test sample contains literally thousands
of different molecular entities, many of which are known to
influence platelet function, including clotting factors, in-
flammatory cytokines, and microparticles. The potential
impact of these constituents is best demonstrated through a
simple but very informative study carried out by Gawaz et
al. (11) in the mid-1990s. Using washed platelets from
healthy volunteers, plasma was added from either acute MI
patients or from control subjects with stable angina. Despite
the platelets being identical, platelet aggregation was mark-
edly greater when combined with the plasma from MI
patients versus that of controls. Similar results were found
for measures of platelet activation and platelet–endothelial
cell adhesion.
These findings form a basis for potentially explaining why
high platelet reactivity has been consistently associated with
worse clinical outcomes, yet some prospective trials altering
antiplatelet function based on ex vivo–measured platelet
reactivity have not translated into improved clinical out-
comes. A better appreciation for the fact that platelets, and
therefore platelet antagonists, play only a partial role in
defining measured platelet reactivity suggests that identify-
ing “optimal” platelet inhibition may not be achievable until
all of the nonplatelet factors influencing measured platelet
function are fully understood.
Current studies. So in light of the above caveats, how are we
to interpret the 2 well-done and interesting platelet func-
tion–based studies in this issue of JACC: Cardiovascular
Interventions? In the study by Ahn et al. (12), on-treatment
platelet reactivity was determined in over 1,200 post-PCI
patients using the VerifyNow P2Y12 assay, and the associ-
ation with locally defined high platelet reactivity and 1-year
outcomes were described. Similar to prior reports, they
found high platelet reactivity to be associated with worse
outcomes, although this was statistically significant only in
the acute MI population. Based on the information de-
scribed earlier, that plasma from acute MI patients leads to
significant differences in platelet function relative to patients
with stable coronary disease (11), it seems logical that the
identification of the most appropriate cut-point for high
platelet reactivity should be based on the patient’s clinical
acuity. Doing so would likely improve its prognostic value,
although what to do with that information still needs to be
defined.
Valgimigli et al. (13) addressed an interesting question
with a very well-done and detailed study in which various
antiplatelet regimens were tested, with the endpoint based
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280on 20 mol/l ADP-induced final aggregation. The premise
of the study was that “suboptimal” platelet inhibition with a
thienopyridine can be identified and then treated with a GP
IIb/IIIa antagonist until “optimal” platelet inhibition is
achieved by the thienopyridine. As logical as that seems, it
is difficult to reconcile that hypothesis with the clinical
results of trials such as BRAVE 3 (Bavarian Reperfusion
Alternatives Evaluation-3) and EARLY ACS (Early Gly-
coprotein IIb/IIIa Inhibition in Non–ST-Segment Eleva-
tion Acute Coronary Syndrome), in which the vast majority
of control-arm patients would have to be assumed to have
“suboptimal” platelet inhibition relative to the GP IIb/IIIa
treatment arm, yet that difference in platelet inhibition did
not lead to differences in clinical outcomes (14,15). How or
whether mixing and matching of P2Y12 antagonists with
P IIb/IIIa inhibitors will reduce ischemic event rates
equires outcomes data and should not be based on platelet
unction results.
Antiplatelet therapies are some of our most potent
nterventions in the treatment and prevention of the com-
lications of atherosclerotic disease. Yet, they remain the
nly routinely utilized drug class in which patients are
reated with a 1-size-fits-all approach, and that flies in the
ace of everything known about genetic and environmental
nfluences and their impact on interindividual variability. But
he desire to individualize therapy needs to be tempered by the
nowledge that there is a long way to go and much still to learn
n our search for the illusive “optimal” platelet inhibition.
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